STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis

Immunology

Volumn 146, Issue 3, 2015, Pages 444-455

  Iyer, Abhirami K ^a   Liu, Jianyun ^a   Gallo, Richard M ^a   Kaplan, Mark H ^a   Brutkiewicz, Randy R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presentation; Janus kinase signal transducer and activation of transcription; Signal transduction

Indexed keywords

CD1D ANTIGEN; CERAMIDE GLUCOSYLTRANSFERASE; GLYCOSPHINGOLIPID; JANUS KINASE; STAT3 PROTEIN; CD1D ANTIGEN, MOUSE; CD1D PROTEIN, HUMAN; GLUCOSYLTRANSFERASE; HLA ANTIGEN CLASS 2; LIPID; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LIPOGENESIS; LYSOSOME; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DENDRITIC CELL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1D; CELL LINE; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, INNATE; LIPIDS; MICE; NATURAL KILLER T-CELLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84943594746     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12521     Document Type: Article

References (65)

1. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36:542-50.
2. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368:161-70.
3. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28:445-89.
4. Vahedi G, Takahashi H, Nakayamada S, Sun HW, Sartorelli V, Kanno Y, O'Shea JJ. STATs shape the active enhancer landscape of T cell populations. Cell 2012; 151:981-93.
5. + T helper cell differentiation. Nat Rev Immunol 2011; 11:239-50.
6. Hand TW, Cui W, Jung YW, Sefik E, Joshi NS, Chandele A, Liu Y, Kaech SM. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A 2010; 107:16601-6.
7. + T cell responses. J Immunol 2010; 185:2116-24.
8. Yao Z, Cui Y, Watford WT et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A 2006; 103:1000-5.
9. Malin S, McManus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P, Strasser A, Busslinger M. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2010; 11:171-9.
10. Bell BD, Kitajima M, Larson RP et al. The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat Immunol 2013; 14:364-71.
11. Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 2003; 19:903-12.
12. Li HS, Watowich SS. Diversification of dendritic cell subsets: emerging roles for STAT proteins. JAKSTAT 2013; 2:e25112.
13. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184:1953-62.
14. Huang H, Li Y, Qi X. Cytokine signaling in the differentiation of innate effector cells. JAKSTAT 2013; 2:e23531.
15. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol 2007; 7:929-41.
16. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol 2007; 314:113-41.
17. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013; 13:101-17.
18. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11:131-42.
19. Juno JA, Keynan Y, Fowke KR. Invariant NKT cells: regulation and function during viral infection. PLoS Pathog 2012; 8:e1002838.
20. Liu J, Shaji D, Cho S, Du W, Gervay-Hague J, Brutkiewicz RR. A threonine-based targeting signal in the human CD1d cytoplasmic tail controls its functional expression. J Immunol 2010; 184:4973-81.
21. + T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci U S A 2002; 99:8197-202.
22. Pathak SS, Blum JS. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules. Traffic 2000; 1:561-9.
23. Bailey JC, Iyer AK, Renukaradhya GJ, Lin Y, Nguyen H, Brutkiewicz RR. Inhibition of CD1d-mediated antigen presentation by the transforming growth factor-β/Smad signalling pathway. Immunology 2014; 143:679-91.
24. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179:1109-18.
25. Roberts TJ, Sriram V, Spence PM et al. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol 2002; 168:5409-14.
26. O'Shea JJ, Gadina M, Kanno Y. Cytokine signaling: birth of a pathway. J Immunol 2011; 187:5475-8.
27. Berzins SP, Ritchie DS. Natural killer T cells: drivers or passengers in preventing human disease? Nat Rev Immunol 2014; 14:640-6.
28. Olszak T, Neves JF, Dowds CM et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 2014; 509:497-502.
29. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278:1803-5.
30. Veenbergen S, Bennink MB, Affandi AJ, Bessis N, Biton J, Arntz OJ, van den Berg WB, van de Loo FA. A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis. Ann Rheum Dis 2011; 70:2167-75.
31. Cerundolo V, Barral P, Batista FD. Synthetic iNKT cell-agonists as vaccine adjuvants - finding the balance. Curr Opin Immunol 2010; 22:417-24.
32. McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res 2015; 3:425-35.
33. Birkholz AM, Howell AR, Kronenberg M. The alpha and omega of galactosylceramides in T cell immune function. J Biol Chem 2015; 290:15365-70.
34. Shin JH, Park SH. The effect of intracellular trafficking of CD1d on the formation of TCR repertoire of NKT cells. BMB Rep 2014; 47:241-8.
35. Wiethe C, Schiemann M, Busch D, Haeberle L, Kopf M, Schuler G, Lutz MB. Interdependency of MHC class II/self-peptide and CD1d/self-glycolipid presentation by TNF-matured dendritic cells for protection from autoimmunity. J Immunol 2007; 178:4908-16.
36. Gallo RM, Khan MA, Shi J, Kapur R, Wei L, Bailey JC, Liu J, Brutkiewicz RR. Regulation of the actin cytoskeleton by rho kinase controls antigen presentation by CD1d. J Immunol 2012; 189:1689-98.
37. Joyce S, Van Kaer L. CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol 2003; 15:95-104.
38. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14:736-46.
39. Dauer DJ, Ferraro B, Song L et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005; 24:3397-408.
40. Jung J-U, Ko K, Lee D-H, Ko K, Chang K-T, Choo Y-K. The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells. Exp Mol Med 2009; 41:935-45.
41. Kinjo Y, Wu D, Kim G et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005; 434:520-5.
42. Mattner J, DeBord KL, Ismail N et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434:525-9.
43. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005; 35:1692-701.
44. Zhou D, Mattner J, Cantu C 3rd et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306:1786-9.
45. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72:ii111-5.
46. Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 2013; 4:15-35.
47. Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 2015; 15:203-16.
48. Zhou F. Molecular mechanisms of viral immune evasion proteins to inhibit MHC class I antigen processing and presentation. Int Rev Immunol 2009; 28:376-93.
49. Kitamura H, Kamon H, Sawa S, Park SJ, Katunuma N, Ishihara K, Murakami M, Hirano T. IL-6-STAT3 controls intracellular MHC class II αβ dimer level through cathepsin S activity in dendritic cells. Immunity 2005; 23:491-502.
50. Chan LL, Cheung BK, Li JC, Lau AS. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-γ-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol 2010; 88:303-11.
51. Gapin L, Godfrey DI, Rossjohn J. Natural Killer T cell obsession with self-antigens. Curr Opin Immunol 2013; 25:168-73.
52. Salio M, Ghadbane H, Dushek O et al. Saposins modulate human invariant Natural Killer T cells self-reactivity and facilitate lipid exchange with CD1d molecules during antigen presentation. Proc Natl Acad Sci U S A 2013; 110:E4753-61.
53. Salio M, Speak AO, Shepherd D et al. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci U S A 2007; 104:20490-5.
54. Speak AO, Cerundolo V, Platt FM. CD1d presentation of glycolipids. Immunol Cell Biol 2008; 86:588-97.
55. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51.
56. Spanoudakis E, Hu M, Naresh K et al. Regulation of multiple myeloma survival and progression by CD1d. Blood 2009; 113:2498-507.
57. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One 2011; 6:e20702.
58. Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol 2014; 5:543.
59. Jakkula E, Leppa V, Sulonen AM et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet 2010; 86:285-91.
60. Flanagan SE, Haapaniemi E, Russell MA et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014; 46:812-4.
61. Milner JD, Vogel TP, Forbes L et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015; 125:591-9.
62. Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH. The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 2011; 3:1167-84.
63. Tan AH, Chong WP, Ng SW, Basri N, Xu S, Lam KP. Aberrant presentation of self-lipids by autoimmune B cells depletes peripheral iNKT cells. Cell Rep 2014; 9:24-31.
64. Chaudhry MS, Karadimitris A. Role and regulation of CD1d in normal and pathological B cells. J Immunol 2014; 193:4761-8.
65. Wilson RP, Ives ML, Rao G et al. STAT3 is a critical cell-intrinsic regulator of human unconventional T cell numbers and function. J Exp Med 2015; 212:855-64.